Biocon Limited

Report DateResearch houseDescriptionRecoAt PriceTarget PriceUpSide
/DownSide
Download
22-Oct-18 Motilal Oswal Positive Committee opinion Neutral 658 625 -5.02
24-Sep-18 Motilal Oswal Favorable regulatory outcome enhances biosimilars prospects Buy 665 625 -6.02
11-Apr-18 SPA Securities Front runner in Biosimilars to guide revenues going ahead 612
3-Dec-17 Motilal Oswal Mylan/ Biocon received Trastuzumab approval in US Neutral 447 485 8.5
27-Oct-17 Nirmal Bang Sec Slowdown In Biosimilar Business As Well As Licensing Income Sell 360 308 -14.44

Upcoming Events and Recent Updates

Download 01-Apr-20
Management Interview - Kiran Mazumdar Shaw,CMD - US FDA has issued an Establishment Inspection Report with Voluntary Action Indicated status to Biocon’s Malaysia Unit  ( updated on Apr 01 2020)
27-Mar-20
Press Release  ( updated on Mar 27 2020)

Analyst Calls / Meets


Management Interviews

01-Apr-20 Kiran Mazumdar ..  
23-Mar-20 Kiran Mazumdar ..  
18-Mar-20 Kiran Mazumdar ..  
20-Feb-20 Kiran Mazumdar ..  
19-Feb-20 Kiran Mazumdar ..  

Investor Presentations


Annual Reports
Source: Reportjunction.com

2018-19  
2017-18  
2016-17  
2015-16  
2014-15  

Research Showcase

22-Oct-18
Motilal Oswal -..
Download
24-Sep-18
Motilal Oswal -..
Download
11-Apr-18
SPA Securities ..
Download
03-Dec-17
Motilal Oswal -..
Download
27-Oct-17
Nirmal Bang Sec..
Download

Results

24-Jan-20 Results
11-Dec-19 Results
24-Oct-19 Results
26-Jul-19 Results
26-Apr-19 Results

AGM/EGM/Board Meetings

23-Jan-20 - Quarterly Results
26-Jul-19 - AGM
25-Jul-19 - Quarterly Results
04-Jun-19 - POM
24-Jan-19 - Quarterly Results

Press Release

27-Mar-20 Press Release
06-Mar-20 Press Release
23-Jan-20 Press Release
06-Jan-20 Press Release
02-Dec-19 Press Release

 

Archived Documents

No Archieved Transcript.